about
Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034Examination of 209 drugs for inhibition of cytochrome P450 2C8In vitro and in vivo metabolism and inhibitory activities of vasicine, a potent acetylcholinesterase and butyrylcholinesterase inhibitorEffect of Methamphetamine on Spectral Binding, Ligand Docking and Metabolism of Anti-HIV Drugs with CYP3A4Predicting in vivo drug interactions from in vitro drug discovery data.Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data.Characterization of cardamonin metabolism by P450 in different species via HPLC-ESI-ion trap and UPLC-ESI-quadrupole mass spectrometryProtection against LPS-induced cartilage inflammation and degradation provided by a biological extract of Mentha spicata.Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.A numerical method for analysis of in vitro time-dependent inhibition data. Part 2. Application to experimental data.Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism.Heterologous expression of human cytochrome P450 (CYP) 2C19 in Escherichia coli and establishment of RP-HPLC method to serve as activity marker.Maraviroc: in vitro assessment of drug-drug interaction potentialDevelopment and validation of a LC-MS/MS method for the in vitro analysis of 1-hydroxymidazolam in human liver microsomes: application for determining CYP3A4 inhibition in complex matrix mixtures.A high-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry.Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5.Development of a Pediatric Physiologically Based Pharmacokinetic Model for Sirolimus: Applying Principles of Growth and Maturation in Neonates and Infants.Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.A sensitive and high-throughput LC-MS/MS method for inhibition assay of seven major cytochrome P450s in human liver microsomes using an in vitro cocktail of probe substrates.The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexiaMetabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes.High-Throughput Cytochrome P450 Cocktail Inhibition Assay for Assessing Drug-Drug and Drug-Botanical Interactions.Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of LovastatinIn vitro screening of drug metabolism during drug development: can we trust the predictions?In vitro metabolic interactions between black cohosh (Cimicifuga racemosa) and tamoxifen via inhibition of cytochromes P450 2D6 and 3A4.Enzyme source effects on CYP2C9 kinetics and inhibitionCYP2C8 and antimalaria drug efficacy.In vitro-in vivo extrapolation of hepatic clearance: biological tools, scaling factors, model assumptions and correct concentrations.Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment.Cytochromes P450: a structure-based summary of biotransformations using representative substrates.In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions.Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers.Identification of key licorice constituents which interact with cytochrome P450: evaluation by LC/MS/MS cocktail assay and metabolic profiling.High-throughput metabolic genotoxicity screening with a fluidic microwell chip and electrochemiluminescence.Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays.Rosiglitazone Metabolism in Human Liver Microsomes Using a Substrate Depletion Method.Characterization of nuciferine metabolism by P450 enzymes and uridine diphosphate glucuronosyltransferases in liver microsomes from humans and animals.Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.The pharmacogenetics of antimalaria artemisinin combination therapy.Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development.
P2860
Q27489828-B531E113-1682-4BB4-B5AD-280E4A1EED74Q28298519-DC816C7E-31BC-4C83-B1E1-FD7022BDC65AQ28545861-4665CAC8-B007-432D-ADF0-61BA91382D56Q28552201-38BD6A3F-5822-47C6-8ACE-0A57FF0F68B7Q31011412-51E7E15C-FCAB-480D-8EFE-454FB3EEDF04Q31054926-D9EAB6DA-8E70-431A-9766-DBF9D3536D93Q33555599-6CD5D524-BC38-47D0-A8DC-157F8BDC6E09Q33575493-38321F3D-94B1-4867-BFD4-E3E3D7C2E307Q34122846-CA07A8F5-4FA8-4641-8360-9DD0C207C810Q34125058-A12D2EAB-647B-4264-9104-207DD66D328DQ34563592-82FE3B0A-4545-4A07-9172-3E86BB00233AQ34578152-A16DDCC2-ABF5-4B49-9336-9E8DFDCD4091Q34594626-8F87A762-7871-4D83-B723-4B9C9CA95FFBQ34722389-888F8335-3BE4-4CD6-B430-F488EE4BAF58Q34941963-93362503-478F-4C06-AD77-E0CF1EB96DF6Q35175018-CD6D4D28-59AA-4E08-A576-628E77E5AF45Q35179536-DC16BF52-D98D-42D2-9A6B-34E2847A83E1Q35187902-9FAB2A48-C7C3-4DA7-9CD3-FA037512D8C0Q35220110-48171FE3-A829-4F1A-B140-7CF90EC3A58AQ35223982-C6CA1D94-F0B9-4269-A308-FC8A11329BA9Q35718630-73FA9D1D-01D7-4FF2-8C87-79FEA96A23CDQ36186126-1950EE8D-34A1-4746-B6F5-351B9F68273DQ36444037-BB2191C6-48D9-4DC8-8606-EE0327F7B520Q36572626-3F26E6CD-28F4-4E4F-A426-9C3B352C773CQ36589050-7E98BB9E-6F50-4FFC-928C-74B67D9D9543Q36648638-8BA6318E-EE73-4CBD-A7F9-AE57909A6390Q36730638-BF97E6B3-D5EC-4DA4-8C1E-179E62E3ADABQ36985051-B2F50791-A2CA-474F-B93C-06EC11AD20FFQ36985086-55F0E507-5110-4A14-93F8-9A29F83726E2Q37079954-DDCB6F3A-282C-49F8-9775-AE566628C884Q37237438-27A24287-E427-49B1-9D44-93A112A7A2DDQ37461886-508E8688-5B92-45F0-9D26-C09DE8DFEFDBQ37469395-E80CC219-EB76-4BD5-838F-2AE9F64707F6Q37511996-A51B1BD9-7C9D-454E-B622-4088269E2F98Q37590883-8303D41F-DB81-447C-A6D7-428D0A65B391Q37653438-17D14AC2-0089-48FF-98FE-763910D976E9Q37729174-8B6F1AA0-6D64-4AF5-83DC-D57E4259B25BQ37845170-19509BE9-5363-4014-B2D3-7914E04D4DD1Q37928680-B9C244D2-0794-4EE6-B94F-CDDC93924451Q37965706-25F68703-8673-40EE-8487-47B3F2A95A40
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Validated assays for human cytochrome P450 activities.
@en
Validated assays for human cytochrome P450 activities.
@nl
type
label
Validated assays for human cytochrome P450 activities.
@en
Validated assays for human cytochrome P450 activities.
@nl
prefLabel
Validated assays for human cytochrome P450 activities.
@en
Validated assays for human cytochrome P450 activities.
@nl
P356
P1476
Validated assays for human cytochrome P450 activities.
@en
P2093
R Scott Obach
Robert L Walsky
P304
P356
10.1124/DMD.32.6.647
P577
2004-06-01T00:00:00Z